Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Screeners

Top Momentum Stocks

Top Quality Stocks

Top Value Stocks

Top Growth Stocks

Comments

Loading...

Otsuka Holdings Stock News

OTSKYOTCPK

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

$23.69

-0.23-0.96%

At close: -

$23.69

0.000.00%

After Hours: Apr 11, 4:39 PM EDT

Otsuka Holdings (OTSKY) Forecast

News

Earnings Otsuka Holdings (OTSKY) Options Guidance Dividends Analyst Ratings Insider Trades Government Trades Short Interest

Latest Otsuka Holdings Stock News | OTC:OTSKY | Benzinga

Get the latest news on Otsuka Holdings stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Otsuka Holdings performance

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Tuesday, December 31, 2024

Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results
Vandana Singh - Dec 31, 2024, 8:15AM

Thursday, October 31, 2024

Otsuka Holdings Q3 EPS $0.52 Up From $0.38 Yo...
Benzinga Newsdesk - Oct 31, 2024, 7:15AM

Tuesday, April 16, 2024

IGC Pharma Says Cannabinoid-Based Drug Candidate Provides Fast Relief With Fewer Side Effects For Alzheimer's-Associated Agitation
Vandana Singh - Apr 16, 2024, 11:47AM

Wednesday, March 20, 2024

Alzheimer's-Focused Small Cap Firm IGC Pharma Releases Data, Candidate Reduces Agitation Compared To Placebo
Vandana Singh - Mar 20, 2024, 1:21PM

Monday, September 18, 2023

One Year Into Kabir Nath's Leadership, Compass Pathways' (NASDAQ: CMPS) Phase 3 Trial For Innovative Treatment Resistant Depression Progressing
Faith Ashmore - Sponsored

Thursday, August 24, 2023

Regulatory Setback For Medtronic's High Blood Pressure Device - FDA Backed Japanese Firms' Similar Device For Uncontrolled Hypertension
Vandana Singh - Aug 24, 2023, 8:45AM

Wednesday, August 23, 2023

Individuals With Uncontrolled Hypertension - FDA Adcomm Panel Just Supported Japanese MedTech's Blood Pressure Treatment Device
Vandana Singh - Aug 23, 2023, 9:34AM

Thursday, May 11, 2023

FDA Approves First Drug To Treat Agitation Symptoms Associated With Dementia Due To Alzheimer's Disease
Happy Mohamed - May 11, 2023, 10:39AM
Japan's Otsuka Pharma-Lundbeck Partnered Depression Drug Gets FDA Approval For Alzheimer's Agitation
Vandana Singh - May 11, 2023, 8:53AM

Thursday, November 03, 2022

Targeting Autosomal Dominant Polycystic Kidney Disease With Novel Approaches
Nick Thomas - Sponsored

Wednesday, August 17, 2022

This Upstart Supplement Company Says It's Making Huge Strides In Selling Its Well-Told Story
Mark Gilman - Sponsored

Friday, August 05, 2022

Akebia's Anemia Drug Disappoints In Mid-Stage COVID-19 Study
Vandana Singh - Aug 5, 2022, 11:12AM

Friday, July 01, 2022

The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact
Vandana Singh - Jul 1, 2022, 8:53AM

Monday, May 16, 2022

Why Are Akebia Therapeutics Shares Falling Today?
Vandana Singh - May 16, 2022, 2:13PM

Wednesday, March 30, 2022

FDA Rejects Akebia Therapeutics' Vadadustat For CKD-Associated Anemia
Vandana Singh - Mar 30, 2022, 3:34PM

Tuesday, June 01, 2021

Akebia Therapeutics Stock Jumps as FDA Accepts Vadadustat US Application in CKD-Related Anemia
Vandana Singh - Jun 1, 2021, 8:58AM

Friday, January 15, 2021

Novavax Hires Regulatory Expert As Coronavirus Vaccine Inches Closer To Emergency Use Filing
Shanthi Rexaline - Jan 15, 2021, 12:47PM

Wednesday, November 25, 2020

JD.com Unit Set For Asia's Largest-Ever Healthcare IPO Above $3B
Aditya Raghunath - Nov 25, 2020, 12:38AM

Friday, August 07, 2020

Earnings Scheduled For August 7, 2020
Benzinga Insights - Aug 7, 2020, 4:02AM

Tuesday, March 24, 2020

Stocks That Hit 52-Week Highs On Tuesday
Benzinga Insights - Mar 24, 2020, 11:35AM

Friday, January 10, 2020

Stocks That Hit 52-Week Highs On Friday
Lisa Levin - Jan 10, 2020, 12:18PM

Monday, December 23, 2019

Stocks That Hit 52-Week Highs On Monday
Lisa Levin - Dec 23, 2019, 10:20AM

Friday, December 20, 2019

Stocks That Hit 52-Week Highs On Friday
Lisa Levin - Dec 20, 2019, 11:59AM

Thursday, August 24, 2017

Otsuka, Mylan Announce License Agreement to Commercialize Delamanid for MDR-TB in High-Burden Countries
Benzinga - Aug 24, 2017, 4:05AM

Thursday, April 27, 2017

4 Things To Know About Akebia's New Vadadustat Collaboration With Otsuka Pharma
Benzinga - Apr 27, 2017, 12:05PM

Sunday, December 07, 2014

FDA Approves Labeling Update of Abilify Maintena for Extended-Release Injectable Suspension
Benzinga - Dec 6, 2014, 9:17PM

Tuesday, December 02, 2014

Benzinga's M&A Chatter for Tuesday December 2, 2014
Benzinga - Dec 2, 2014, 5:40PM
UPDATE: Otsuka to Acquire Avanir for $17.00/S...
Benzinga - Dec 2, 2014, 4:59AM
Avanir Pharmaceuticals to be Acquired by Otsuka Pharmaceutical for $3.5B
Benzinga - Dec 2, 2014, 4:58AM

Monday, October 07, 2013

Astex Pharmaceuticals Announces Expiration of HSR Waiting Period for Otsuka Tender Offer
Benzinga - Oct 7, 2013, 6:06AM

Friday, April 12, 2013

Otsuka's NDA for Tolvaptan for Autosomal Dominant Polycystic Kidney Disease , Accepted for Review by FDA
Benzinga - Apr 12, 2013, 5:58AM

Popular Channels

PreMarket Playbook
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2025 Benzinga | All Rights Reserved